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ABSTRACT
Objectives: This study aims to investigate the Sudanese community pharmacists knowledge and practice regarding cardiovascular disease (CVD) risk 
assessment services.
Methods: A non-interventional, descriptive, cross-sectional community pharmacy-based survey was conducted on 190 community pharmacies in 
Khartoum state.
Conclusion: The current knowledge and practice of CVD risk assessment are inadequate and need fundamental development. CVD services were 
provided by respondents on voluntary bases without full knowledge or appropriate training on proper assessment and evaluation of the risks that 
they measured. This needs to change if pharmacy’s potential is to be reached. Collaboration between health authorities and universities is essential 
to acknowledge the new roles of the pharmacist and provide the appropriate knowledge, training, and practice standards needed to promote and 
implement the change process that is required.
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INTRODUCTION
The World Health Organization figures estimate that cardiovascular 
disease (CVD) caused the death of 17.7 million people worldwide, 
being the largest cause of death. CVD is predicted to remain the 
number one cause of death globally in the foreseeable future. Over 
three-quarters of CVD deaths take place in low- and middle-income 
countries [1]. In the Sudan, CVD is rated third of the top 10 causes of 
death in hospitals and hypertension and diabetes mellitus (DM) are 
two of the top 10 leading diseases for hospitals admission [2]. Mukesh 
et al. investigated CVD prevalence and drug utilization patterns at a 
tertiary care hospital in Northeastern India. Their findings indicated 
that hyperlipidemia, hypertension, and ischemic heart disease were the 
most frequently diagnosed diseases and diabetes, anemia, and asthma 
were comorbidities associated with CVD. Male patient, 60–90 years, 
was most affected and admitted to the department of cardiology [3].
CVD has a substantial impact on people’s health and quality of life. It 
also causes an increased use of health-care resources and services, 
representing a significant proportion of health-care expenditure. CVD 
risk assessment services could identify patients with poorly controlled 
risk factors and significantly reduce their risk for cardiovascular events. 
Despite the fact that CVD risk is associated with hypertension, diabetes, 
dyslipidemia, and smoking, these risk factors remain poorly identified 
and controlled. Their early identification and treatment are essential 
to prevent excess morbidity, mortality, and unnecessary health-care 
spending.
Community pharmacists are ideally placed to assist in the detection, 
education, and referral of individuals at elevated risk of CVD and 
similar conditions. The feasibility, potential benefits, and effectiveness 
of a community pharmacy-based CVD risk screening services are 
well documented. Systematic reviews, meta-analysis, and multicenter 
randomized controlled trials showed that pharmacies are feasible sites 
for such services, where a significant number of previously unknown 
cases of risk factors such as hypertension, hypercholesterolemia, and 
diabetes were identified [4-6]. Many studies demonstrated successful 
community pharmacist interventions in identification and targeting 
asymptomatic individual with high risks to develop CVD and referral 
to practitioners for further follow-up [7-10]. Adults in England aged 
40–74 years are eligible for the assessment of CVD risk based on their 
body mass index, cholesterol, blood pressure, and alcohol use. People 
having a health check may also be tested for type 2 diabetes if the 
doctor thinks it is necessary. The results of the health check are given 
as an overall cardiovascular risk score (low, moderate, or high). Low 
and high risks are defined as less than 10% and more than 20% chance 
of a heart or circulation problem in the next 10 years. Pharmacies in 
the United Kingdom dispense prescriptions and other medicines, but 
increasingly also offer testing for common conditions, and provide 
advice on minor ailments. In addition, some pharmacies provide checks 
of blood pressure, cholesterol, and blood glucose and offer screening 
for chlamydia and allergies [11].
A comprehensive study project investigating the current situation of 
CVD risk screening services in community pharmacies in the Sudan 
was carried out by the authors. There were five aspects of the project; 
the awareness, attitude, knowledge, and practice of participating 
community pharmacists as well as the barriers of implementation. 
The awareness, attitude, and barriers were reported in a previously 
published article by the authors [12]. The aim of the present article 
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Results: The response rate was 91%. The obese and elderly received the highest ratings for CVD risk assessment services. 
Hypertension, hyperlipidemia, type 1 and type 2 diabetes mellitus, and age groups >55 and 36–55 years were the most targeted categories for 
screening.  Variable responses were reported regarding the type of  fasting lipid profile  that  is  to be screened.  Although most participants had the 
appropriate equipment for screening, only a few had cholesterol measure kits. One-third of the participants claimed to have screening evaluation forms 
and 27% reported the use of cardiovascular risk charts or calculators. Overwhelming majority had no documentation records and the most available 
reference is the BNF.
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is to address the knowledge and practice of Sudanese community 
pharmacists regarding CVD risk screening services.
METHODS
The study was approved by the Faculty of Pharmacy, University of 
Khartoum Ethical Research Committee. The methodological details of 
the study design, setting and population, sampling procedure, and data 
collection as well as piloting were described earlier in another article 
published by the same authors [12]. The total number of questions 
that are related to this article was 17. Both closed- and open-ended 
questions were used. The demographic characteristics of participating 
community pharmacists were documented using four questions. 
Community pharmacists knowledge and practice of screening services 
were investigated using five and eight questions, respectively. At the end 
of the questionnaire, pharmacists were invited to express comments 
regarding the development of community pharmacy practice in the 
Sudan.
Data analysis
The responses in each section were subjected to frequency analysis 
using SPSS® (version 13) for descriptive statistics. Results were 
expressed as frequency and percentage.
RESULTS
The questionnaire reliability was considered acceptable (α=0.7 [95% 
confidence interval, 0.62–0.77]). A total of 190 questionnaires were 
distributed. One hundred and seventy-three completed questionnaires 
were returned, after one to three reminders, giving a response rate of 
91%. The majority of participants aged 22–30 years with B. Pharm and 
up to 5 years’ practice experience (Table 1).
Fifty-nine of the 173 participants claimed to actually perform 
CVDs risk screening services in their pharmacies (Fig. 1). They 
were the focus of this article. For assessing their knowledge and 
practice, a number of questions were formulated to ensure that 
they provided the services according to standard procedures. The 
questions investigated the targeted candidates, risks and age groups, 
availability of patient evaluation forms, screening equipment, risk 
factor assessment tools, and references. In addition to, the methods 
used to evaluate CVD risk.
The obese received the highest ratings for screening followed by the 
elderly than the smokers (Fig. 2).
CVD risks that community pharmacists mostly screen were 
hypertension, hyperlipidemia, and DM (Fig. 3).
As can be shown in Fig. 4, the respondents mostly targeted only 
two age groups for hypertension screening. About 80% of the 
participants considered that blood pressure is high when the reading 
is 150/95 mmHg, 74% considered it abnormal if the reading is 
140/90 mmHg, and 5% considered it high when it is 130/85 mmHg.
The majority of respondents claimed to perform screening for type 1 
and type 2 DM. A considerable number does not know the type of 
diabetes that requires screening and a small number of screens for 
gestational DM (GDM) (Fig. 5). About 44% of the study participants 
indicated that they perform recheck for negative results of diabetes 
every 1 year, 6% claimed it is done every 2 years, and 22% does not 
know.
Variable responses were reported regarding the type of fasting lipid 
profile to screen as a measure of total count of lipids (Table 2).
Most of the participants had a glucometer and about one-half had 
sphygmomanometer and weight and height scales in their community 
pharmacies. Only a few had cholesterol measure kits (Fig. 6). About 
34% of the participants reported the use of patient’s evaluation forms.
Fig. 1: Performance of cardiovascular disease screening services 
in respondent’s pharmacies
Fig. 2: Targeted customers for cardiovascular disease risk screening
Fig. 3: Cardiovascular disease risks that necessitate screening











B. Pharm 170 (98.3)









Table 2: Type of fasting lipid profile screened by participants





None of the above-mentioned types 56
Other measures 6
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Fig. 7 illustrates reference available at the surveyed community 
pharmacies, with the BNF being the most available one.
In response to the tools used for evaluating CVD risk, one-half of the 
participants did not know how to evaluate, about one-quarter do not 
use any evaluation tools and the rest were familiar with the CVD risk 
charts and calculators (Fig. 8). Overwhelming majority (94%) has no 
documentation records in their pharmacies.
DISCUSSION
This study aimed to explore knowledge and practice of CVD risk 
screening in Sudanese community pharmacies. Although community 
pharmacists in many countries assumed the responsibility of 
implementing CVD risk assessment services, in the current study, only 
one-third of participants claimed to perform these services.
The majority of participants were young with a B. Pharm. A study 
in Australian showed that younger pharmacists and pharmacies in 
regional shopping centers were associated with a higher level of 
preventive services for CVD [13]. This indicates that patient-focused 
services in community pharmacies can be applicable at any educational 
level after graduation following appropriate knowledge and training.
The most targeted candidates mentioned by the participants for CVD 
screening services; the obese, elderly, and smokers give indication 
that they are aware of to whom the service should be offered. At least 
one-third of all disease burdens worldwide are caused by tobacco, 
The age groups targeted for hypertension screening by the majority 
of participants represent a positive finding since all adults 40 years 
onward, who have no history of CVD or diabetes, and who are not 
already on treatment for blood pressure or lipids, should be considered 
for an opportunistic comprehensive CVD risk assessment in primary 
care. Younger adults (<40 years) with a family history of premature 
atherosclerotic disease should also have their cardiovascular risk 
factors measured [14].
Community pharmacists are in a position to reinforce the implementation 
of a variety of clinical guideline treatment goals for hypertension, such 
as systolic BP <140 mmHg and diastolic BP <90 mmHg, total cholesterol 
<5 mmol/L, and hemoglobin A1c <7% [14,16,17]. The current study 
found that the majority of community pharmacists are aware of the 
clinical guidelines of targeted blood pressure during screening. This 
is very significant for patient’s counseling and referral. Nasution et al. 
showed that counseling in hypertensive patients improved adherence 
to prescribed medications and reduced blood pressure and the risk of 
CVD [18].
Fig. 4: Target age groups for hypertension screening
Fig. 5: Types of diabetes that necessitate screening
Fig. 6: Equipment available for screening purposes
Fig. 7: References available in respondent’s pharmacies
Fig. 8: Tool used for the assessment of cardiovascular disease risk
alcohol, blood pressure, cholesterol, and obesity. Furthermore, more
 than three-quarters of CVD results from tobacco use, high 
blood  pressure,  cholesterol,  or  their  combination  [14]. 
Hypertension was the most commonly reported cardiovascular 
risk screened by the participants. As has been mentioned earlier,
 in Sudan, hypertension and diabetes are two of the top 10 
leading  diseases  for  hospital  admission  [2].  Accordingly, 
community pharmacists must not ignore that comorbidity of CVD
 occurs with diabetes and that diabetes remains as one of 
the most serious risks in Sudan and should be focused on and
 screened as well as hypertension. Based on expert opinion, the 
American Diabetes Association recommends screening for type 2 
DM every 3 years in all adults beginning at age 45 years. Testing 
should  be  done  every  2  years  starting  at  10  years  of  age  or  at 
the onset of puberty if it occurs at a younger age. Screening for
 type 1 DM is not recommended. The participants stated performance
 of  screening  for  both  type  2  and  type  1  DM  and  only  a  few 
screened  GDM.  Risk  assessment  for  GDM  should  occur  at  the  first 
prenatal visit. Women at high risk (positive family history, history of
 GDM, marked obesity, or member of a high-risk ethnic group) should 
be screened as soon as feasible [15].
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One of the main requirements for implementing screening services in 
community pharmacies is the availability of patient evaluation forms. 
In the current study, the majority of community pharmacist performed 
screening services without patient evaluation forms, missing one of 
the basic rules of practice. Some screening equipment were available 
to participants. For a successful screening service, all equipment 
must available and community pharmacists must be trained on their 
use, including appropriate screening and assessment techniques. The 
majority of participants were performing CVD risk screening services 
without using primary prevention methods. Therefore, they were not 
able take decision for estimating at-risk individuals for developing 
cardiovascular problems over 10 years, and hence, no referral actions 
or health promotion advices were given. Accordingly, pharmacist 
contribution to cardiovascular risk preventive screening services was 
self-effacing. Peterson et al. indicated that a pharmacy-based CVD risk 
profile screening together with appropriate educational programs has 
the potential to cost-effectively identify and refer many undiagnosed 
individuals at high risk of cardiovascular events, and help decrease the 
national burden of heart disease [7].
Only one-quarter of the participants reported the use of CVD risk 
calculators and charts. In general, the most commonly used tools for CVD 
risk assessment are the New Zealand Guidelines, the Sheffield Table, and 
the Joint British Societies’ cardiovascular risk prediction charts [16]. 
Cardiovascular risk charts are intended to allow the introduction of the 
total risk stratification approach for the management of CVD [14,16]. 
Risk assessment in primary prevention is facilitated by computer 
software to make the estimations. However, inbuilt assumptions and 
default values used by particular packages need to be recognized to 
avoid misinterpretation. A computer-based decision support has yet 
to be demonstrated to affect clinical decisions or clinical outcomes. 
The risk charts are accessible through websites [17]. As an example, 
the first step in assessing a person’s CVD risk is to measure the major 
cardiovascular risk factors; smoking habit, blood pressure, and lipids 
(total cholesterol and high-density lipoprotein) and then use the Joint 
British Societies’ cardiovascular risk prediction chart (or computer 
program) to estimate total CVD risk according to age and gender [16]. 
With the current community pharmacy practice situation and the 
available facilities to measure CVD risks, cardiovascular risk prediction 
charts for primary prevention available in the BNF can be used if 
computer programs are not available [14,19,20].
A full range of records should accompany any service provided by a 
pharmacist and the service should be fully auditable. Patient’s details 
should be stored, electronically or otherwise, along with their consent 
forms, blood pressure, glucose, cholesterol, or other measurements 
together with any recommendations made. Unfortunately, it was found 
that overwhelming majority of participants had no records in their 
pharmacies. This reflects that no documentation had occurred within 
the current practice, which interferes with the fact that documenting 
the care provided in practice reflects commitment to the patient, 
adherence to practice standards, and the desire to learn from clinical 
experience [19]. Pharmacists need to continue their own education 
regarding CVD so that they can educate and support patients, identify 
patients needing medical attention, and serve as a community resource 
for promoting a healthy lifestyle.
CONCLUSION
CVD screening services are underprovided in community pharmacies 
in Khartoum state and need further development. The limited services 
provided, were performed on voluntary basis without appropriate 
knowledge and practice standards. Unfortunately, these services are not 
officially recognized as part of the Sudanese pharmacist responsibilities 
and do not represent one of the current roles of the pharmacist. 
Collaboration between the Ministry of Health, the Pharmaceutical 
and Medical Associations, and Universities for the recognition of CVD 
risks screening services as well as provision of knowledge and training 
programs for community pharmacists is essentially needed.
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